Related Experiment Videos
[Glucocorticoid treatment in UC]
Toshifumi Ashida1, Yutaka Kohgo
1Third Department of Internal Medicine, Asahikawa Medical College.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 11, 2005
Summary
Glucocorticoids (GC) are key for ulcerative colitis (UC) treatment, but low doses don't prevent relapse. Measuring GC receptor isoforms in PBMCs may predict patient response to GC therapy.
Area of Science:
- Pharmacology and Gastroenterology
- Immunology
Context:
- Glucocorticoids (GC) are central to ulcerative colitis (UC) treatment strategies.
- Current guidelines recommend high-dose intravenous GC for severe UC and oral or enema forms for moderate to localized disease.
- However, low-dose GC has demonstrated ineffectiveness in preventing UC relapse.
Purpose:
- To explore the role of glucocorticoid receptor (GC) expression in UC treatment.
- To investigate the potential of GC receptor isoforms in predicting GC sensitivity in UC patients.
Summary:
- Glucocorticoid administration is a cornerstone in managing ulcerative colitis (UC).
- While high doses are used for severe cases, low-dose GC is ineffective for relapse prevention.
- Glucocorticoid receptor (GC) expression is critical for GC's therapeutic effects, with the beta isoform potentially linked to unresponsiveness.
- Measuring GC receptor isoforms in peripheral blood mononuclear cells (PBMC) may predict GC sensitivity in UC patients.
Impact:
- This research could lead to personalized medicine approaches for UC treatment.
- Identifying GC-unresponsive patients early can help avoid ineffective therapies and guide alternative treatment strategies.
- Optimizing GC therapy and receptor isoform analysis can improve the quality of life (QOL) for UC patients by enabling timely GC tapering after remission.